These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 27435398)

  • 1. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity.
    Tysome JR; Li X; Wang S; Wang P; Gao D; Du P; Chen D; Gangeswaran R; Chard LS; Yuan M; Alusi G; Lemoine NR; Wang Y
    Clin Cancer Res; 2012 Dec; 18(24):6679-89. PubMed ID: 23091113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local Delivery of OncoVEX
    Moesta AK; Cooke K; Piasecki J; Mitchell P; Rottman JB; Fitzgerald K; Zhan J; Yang B; Le T; Belmontes B; Ikotun OF; Merriam K; Glaus C; Ganley K; Cordover DH; Boden AM; Ponce R; Beers C; Beltran PJ
    Clin Cancer Res; 2017 Oct; 23(20):6190-6202. PubMed ID: 28706012
    [No Abstract]   [Full Text] [Related]  

  • 4. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
    Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
    Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.
    Dhar D; Spencer JF; Toth K; Wold WS
    J Virol; 2009 Mar; 83(5):2130-9. PubMed ID: 19073718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response.
    Jung BK; Oh E; Hong J; Lee Y; Park KD; Yun CO
    Biomaterials; 2017 Dec; 147():26-38. PubMed ID: 28923683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity.
    Yan Y; Li S; Jia T; Du X; Xu Y; Zhao Y; Li L; Liang K; Liang W; Sun H; Li R
    Tumour Biol; 2015 Jun; 36(6):4535-43. PubMed ID: 25627006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.
    Workenhe ST; Simmons G; Pol JG; Lichty BD; Halford WP; Mossman KL
    Mol Ther; 2014 Jan; 22(1):123-31. PubMed ID: 24343053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.
    Zhang L; Hedjran F; Larson C; Perez GL; Reid T
    Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
    Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
    Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
    Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
    Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
    Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
    Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
    Yu F; Wang X; Guo ZS; Bartlett DL; Gottschalk SM; Song XT
    Mol Ther; 2014 Jan; 22(1):102-11. PubMed ID: 24135899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic adenovirus characterization: activity and immune responses.
    Gil-Hoyos R; Miguel-Camacho J; Alemany R
    Methods Mol Biol; 2014; 1089():117-32. PubMed ID: 24132482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
    Chen D; Huang L; Zhou H; Zhang Y
    Front Immunol; 2021; 12():615089. PubMed ID: 33717103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds.
    Wold WS; Toth K
    Adv Cancer Res; 2012; 115():69-92. PubMed ID: 23021242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
    Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
    J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syrian hamster tumor model to study oncolytic Ad5-based vectors.
    Dhar D; Toth K; Wold WS
    Methods Mol Biol; 2012; 797():53-63. PubMed ID: 21948468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of JNK phosphorylation as a molecular target to enhance adenovirus replication, oncolysis and cancer therapeutic efficacy.
    Wechman SL; Rao XM; Gomez-Gutierrez JG; Zhou HS; McMasters KM
    Cancer Biol Ther; 2018; 19(12):1174-1184. PubMed ID: 30067431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.